<DOC>
	<DOCNO>NCT00717314</DOCNO>
	<brief_summary>This 2 arm study compare efficacy safety switch CellCept combine different regimen reduce calcineurin inhibitor ( CNI ) patient liver transplant . Patients currently receive CNI treatment randomize one 2 group receive either 1 ) CellCept 2.0g/day po bid + 50 % reduction CNI baseline 2 ) CellCept 2.0g/day po bid + &gt; =75 % reduction CNI baseline . The anticipated time study treatment 1 year , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study CellCept ( Mycophenolate Mofetil ) Combined With Calcineurin Inhibitors Liver Transplant Patients .</brief_title>
	<detailed_description />
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; single organ recipient liver allograft ; CNIbased immunosuppressive regimen prior study entry regimen adjustment ; &gt; =6 month posttransplant , renal dysfunction ( serum creatinine 140300micromol/L entry ) ; negative pregnancy test woman childbearing potential ; contraception must take begin study drug therapy 6 week last dose study medication . treatment CellCept product delivers mycophenolic acid within 3 month prior recent switch CellCept relevant enrollment ; know contraindication CNI , corticosteroid CellCept .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>